-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
TScan Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2024.
- TScan Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$34.1M, a 38.6% decline year-over-year.
- TScan Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$112M, a 35.1% decline year-over-year.
- TScan Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$93.5M, a 40.3% decline from 2022.
- TScan Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$66.6M, a 37% decline from 2021.
- TScan Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$48.6M, a 85.4% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)